Clinical Outcomes of CLL and MCL Patients Treated With Ibrutinib: An Observational Retrospective Medical Chart Review From India
Phase of Trial: Phase IV
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 27 Jul 2018 Planned primary completion date changed from 16 Jul 2018 to 30 Nov 2018.
- 29 Jun 2018 Planned End Date changed from 31 Jul 2018 to 30 Nov 2018.
- 29 Jun 2018 Status changed from not yet recruiting to recruiting.